58 results about "Spondarthritis" patented technology

The invention discloses a novel benzofuran component in eupatorium chinense and application of the benzofuran component in anti-inflammatory activity. The obtained compound is separated from an eupatorium chinense extract. The eupatorium chinense root extract is separated by using an extraction method, macroporous adsorption resin impurity removal, Sephadex LH-20 gel column chromatography, high performance liquid chromatography and other methods. According to the present invention, all the separated compounds and the analogues thereof have good inhibition activity on target cyclooxygenase-2 of inflammation-related diseases, and have good inhibition activity on COX-2 enzyme, and the molecular docking experiment results show that the compounds and the target proteins have good binding energy. Therefore, the compound can be used for preparing drugs for treating inflammatory related diseases, or anti-inflammatory and analgesic drugs, or tumor drugs by inhibiting COX-2 enzyme, such as drugs for rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, Alzheimer's disease and the like, and related natural lead compounds are provided.

The invention discloses a compound for regulating the activity of micro RNA-124, the compound has a structure as shown in a formula (I), and the compound can be used for preventing or treating inflammatory diseases. Comprising but not limited to inflammatory bowel disease, rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, Alzheimer's disease, Paragins disease, osteoarthritis, atherosclerosis, ankylosing spondylitis, psoriasis, dermatitis, Sjogren syndrome, bronchitis, asthma and inflammation associated with colon cancer; the compounds are useful for treating colon cancer, and in particular inflammatory bowel disease, rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, osteoarthritis, ankylosing spondylitis, psoriasis, Sjogren syndrome, bronchitis, and inflammation associated with colon cancer.

The present invention provides an antibody or a conjugated fragment of a citrulline-containing epitope used for the treatment or prevention of diseases associated with the release of extracellular traps from cells, such as neutrophil extracellular trap (NET)-associated pathology (NET-associated pathology) or eosinophil extracellular trap (EET)-associated pathology (EET-associated pathology), and provides a method comprising administering at least one dose of the antibody at a specific concentration. The present invention also provides the method itself. NET-related pathologies include systemic lupus erythematosus (SLE), lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia, asthma, allergic rhinovirus exacerbated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, or wound healing in diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in This includes other NET-related pathologies, such as the health of transplanted organs in vivo or ex vivo.The present invention also relates to wound healing in SLE, lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid antibody syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia asthma, allergic rhinovirus exacerbating asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, thrombotic disease, cardiovascular disease, or diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in vivo or ex vivo The present invention provides pharmaceutical compositions and methods for treating and preventing NET-related pathologies, including other NET-related pathologies such as the health of transplanted organs in vivo. NET-related pathologies include eosinophilic diseases or conditions of the skin, respiratory eosinophilic diseases or conditions, gastrointestinal eosinophilic diseases or conditions, allergic diseases or conditions, or eosinophilic diseases or conditions such as helminthic, fungal, viral or bacterial infections.

The disclosure is directed to pharmaceutical products and stable liquid compositions of IL-17 antibodies and antigen-binding fragments thereof, e.g., AIN457 (secukinumab), and processes of making these pharmaceutical products and compositions. The disclosure is also directed to the use of these pharmaceutical products and liquid compositions (e.g., as part of a kit having instructions for use) for the treatment of various IL-17-mediated disorders (e.g., autoimmune disorders, such as psoriasis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis).

This disclosure provides substituted 6-imidazopyridazine compounds for the modulation of IL-17A and pharmaceutical compositions thereof. These compounds are useful in the treatment of inflammatory conditions such as psoriasis, psoriatic arthritis, or ankylosing spondylitis.

The disclosure is directed to pharmaceutical products and stable liquid compositions of IL-17 antibodies and antigen-binding fragments thereof, e.g., AIN457 (secukinumab), and processes of making these pharmaceutical products and compositions. The disclosure is also directed to the use of these pharmaceutical products and liquid compositions (e.g., as part of a kit having instructions for use) for the treatment of various IL-17-mediated disorders (e.g., autoimmune disorders, such as psoriasis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis).

This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as psoriasis, psoriatic arthritis or axial (spinal) spondyloarthritis (ax-SpA), including ankylosing spondylitis and non-radiographic ax-SpA, utilizing anti-IL-23A antibodies.

The present application relates to the technical field of data processing, in particular to a comprehensive management system for ankylosing spondylitis. The monitoring state values generated by a plurality of continuous historical monitoring time periods corresponding to the current monitoring time are fused, a numerical sequence composed of the plurality of monitoring state values is traversed, and a state value distribution hash table is constructed. According to the state value distribution hash table, a sub-determination value corresponding to each monitoring state value is generated. An abnormality determination value corresponding to the current monitoring time is generated, which avoids errors in the relevant information obtained by a single monitoring time, and thus avoids errors in the evaluation index obtained. The present application overcomes the problem in the prior art that although the questionnaire can be used to collect various related symptom information of the AS patient in the current period, the relevant information deviation is generated due to the influence of the subjective feeling of the user and other unexpected situations, and thus a large error is generated in the evaluation index, which cannot be accurately warned.

The present disclosure relates to crystalline forms of N-(l-(tert-butyl)-lH-pyrazol-4-yl)-2-( 4-((6-((methylsulfonyl)quinolin-4-yl)oxy)-3-methylphenyl)acetamide of formula (II) and crystalline forms of salts thereof. The compound of formula (II) is a RIPK2 inhibitor for the treatment of e.g. inflammatory diseases, autoimmune diseases, granulomatous disease, neurodegenerative diseases or cancer, and more specifically for the treatment of inflammatory bowel disease, such as Crohn's disease or ulcerative colitis, rheumatoid arthritis, inflammatory arthritis, peritonitis, ischemia reperfusion injury in kidney transplant, non-alcohol steatohepatitis, alcohol steatohepatitis, insulin-resistant type 2 diabetes, allergic rhinitis, asthma, atopic dermatitis, Sjogren's syndrome, spondyloarthritis, ankylosing spondylitis, pemphigus vulgaris, idiopathic plasmacytic lymphadenopathy, atherosclerosis, myocardial infarction, thrombosis, alpha-synucleinopathy, Parkinson's disease, dementia with Lewy body, multiple system atrophy, Alzheimer's disease, amyotrophic lateral sclerosis, and chronic obstructive pulmonary disease

The invention provides a kit for HLA-B27 allele typing detection. The kit comprises an amplification primer covering an HLA-B exon region, and a PCR (Polymerase Chain Reaction) reaction solution. According to the detection method, 1 / 2, 3 and 4 exons of HLA-B27 are covered, DNA samples are amplified and sequenced through a special primer group, HLA-B locus alleles are obtained through database comparison, interference of other homologous high locus gene sequences is avoided, and the accuracy of typing results is improved. According to the method, the inherent defects of a traditional method in the aspects of coverage range, anti-interference capability, operation convenience and the like are overcome, innovative improvement is achieved in multiple technical levels, an efficient and reliable tool is provided for early screening of ankylosing spondylitis, subtype correlation research and individualized treatment, and the method is suitable for popularization and application. The detection accuracy, sensitivity and practicability are obviously improved.

The invention provides certain difluorotetrahydropyran-imidazotriazine compounds of formula I as IL-17A inhibitors, pharmaceutical compositions thereof, and methods of using a compound of formula I to treat psoriasis, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, hidradenitis suppurativa, systemic lupus erythematosus, palmoplantar pustulosis (PPP), atopic dermatitis, asthma, non-infectious uveitis, or COPD.

The disclosure herein relates to the development and production of novel antibodies and antigen-binding fragments thereof that bind to TL1A and are useful in the treatment, prevention, and diagnosis of diseases, disorders, or inflammation, including, for example, autoimmune diseases, including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis, including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of the final antibody structure are designed de novo by a computer system and its data training set, without reference to a particular reference molecule.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition with effects of tonifying kidney, dispelling cold and dredging collaterals as well as a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 20 to 40 parts of rhizoma cibotii, 5 to 15 parts of fructus psoraleae, 10 to 20 parts of cortex eucommiae, 10 to 20 parts of caulis sinomenii, 20 to 40 parts of caulis spatholobi, 1 to 10 parts of scorpio, 10 to 20 parts of honeycomb and 10 to 20 parts of rhizoma drynariae. The preparation method comprises the following steps: adding a solvent into the rhizoma cibotii, the fructus psoraleae, the cortex eucommiae, the caulis sinomenii, the caulis spatholobi, the scorpio, the honeycomb and the rhizoma drynariae, extracting, and filtering to obtain an extracting solution; and concentrating the extracting solution to obtain thick paste. The traditional Chinese medicine composition disclosed by the invention is mainly used for tonifying kidney and strengthening governor meridian, is not forgotten to activate blood and remove stasis, and is combined with insect medicines for dispelling wind and dredging collaterals, warming kidney and tonifying deficiency to play a synergistic effect, so that the treatment effect of the ankylosing spondylitis can be remarkably enhanced.

The application relates to the technical field of animal models, and discloses a construction method and application of an ectopic ossification arthritis animal model. 91‑115 After being mixed and emulsified with chicken type II collagen as an antigen, animals are immunized to obtain the animal model, which is referred to as a C2V7 model. The arthritis model constructed by the application has high success rate, short time consumption and easily-obtained modeling materials. The model can simulate the onset process of arthritis with obvious ectopic ossification characteristics such as ankylosing spondylitis, enthesial-related arthritis and psoriatic arthritis, objectively reflects the pathological process and pathological characteristics of ectopic ossification arthritis, and provides a new research platform for related research.

The application belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating ankylosing spondylitis and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw materials: Psoralea 6-18g, Herba Epimedii 6-20g, prepared Fufangpi 3-15g, Rhizoma Drynariae 6-20g, Radix Cyathulae 9-18g, Radix et Rhizoma Ampelopsis 12-24g, Radix et Rhizoma Clematis 6-12g, Herba Lysimachiae 10-30g, Radix et Rhizoma Smilacis glabrae 10-30g, Radix Paeoniae Rubra 9-15g, natural copper 6-12g, Geotrupes 3-9g, Radix et Rhizoma Ampelopsis 6-12g, Rhizoma Notopterygii 6-15g, Radix Angelicae Pubescentis 6-15g, Radix Angelicae Pubescentis 6-12g, Radix et Rhizoma Baphicacanthis 3-9g, Radix et Rhizoma Baphicacanthis 6-15g, Radix et Rhizoma Baphicacanthis 6-15g, Radix et Rhizoma Baphicacanthis 6-15g, Radix et Rhizoma Baphicacanthis 6-15g, Radix et Rhizoma Baphicacanthis 6-15g, Radix et Rhizoma Baphicacanthis 6-15g, Radix et Rhizoma Baphicacanthis 6-15g, Radix et Rhizoma Baphicacanthis 6-15g, Radix et Rhizoma Baphicacanthis 6-15g, Radix et Rhizoma Baphicacanthis 6-15g, Radix et Rhizoma Baphicacanthis 6-15g, Radix et Rhizoma Baphicacanthis 6-15g, Radix et Rhizoma Baphicacanthis 6-15g, Radix et Rhizoma Baphicacanthis 6-15g, Radix et Rhizoma Baphicacanthis 6-15g, Radix et Rhizoma Baphicacanthis 6-15g, Radix et Rhizoma Baphicacanthis 6-15g, Radix et Rhizoma Baphicacanthis 6-15g, Radix et Rhizoma Baphicac

The present disclosure relates to pharmaceutical products and stable liquid compositions of IL-17 antibodies and antigen-binding fragments thereof, such as AIN457 (secukinumab), and processes for manufacturing these pharmaceutical products and compositions. The present disclosure also relates to the use of these pharmaceutical products and liquid compositions (e.g., as part of a kit with instructions for use) for the treatment of various IL-17-mediated diseases (e.g., autoimmune diseases, such as psoriasis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis).

This invention proposes a traditional Chinese medicine compound for treating ankylosing spondylitis of the kidney-deficiency and damp-heat type accompanied by gastrointestinal dysfunction, along with its preparation method, belonging to the field of traditional Chinese medicine technology. The compound consists of Smilax glabra, Bletilla striata, Paris polyphylla, Geranium wilfordii, Dioscorea hypoglauca, Patrinia scabiosaefolia, Dipsacus asper, Drynaria fortunei, Pyrola rotundifolia, Clematis chinensis, Pheretima aspergillum, Lycopodium clavatum, Corydalis yanhusuo, Paeonia lactiflora, Atractylodes macrocephala (fried), Coix lacryma-jobi (raw), Aucklandia lappa, and Glycyrrhiza uralensis. This invention combines these herbs to achieve a synergistic effect, collectively clearing heat and dampness, strengthening the spleen and kidneys, and unblocking the meridians. The overall formula addresses both strengthening the body's foundation and eliminating pathogenic factors, ensuring unobstructed meridian flow and relieving arthralgia. This compound has the functions of clearing heat and dampness, strengthening the spleen and kidneys, and unblocking the meridians. It offers a short treatment course, rapid efficacy, low recurrence rate after cure, few side effects, and is inexpensive and convenient to use for treating ankylosing spondylitis with gastrointestinal dysfunction.

The invention provides certain dimethyltetrahydropyran-imidazotriazine compounds of formula (I) as IL-17A inhibitors, pharmaceutical compositions thereof, and methods of using a compound of formula I to treat psoriasis, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, hidradenitis suppurativa, systemic lupus erythematosus, palmoplantar pustulosis (PPP), atopic dermatitis, asthma, non-infectious uveitis, or COPD.

A method to prevent a disease, comprising: (1) administering a peptide comprising Delta6PV into a subject comprising a human or an animal; wherein the disease comprises one of more of Type 1 Diabetes, Rheumatoid arthritis, Lupus, Sjogren's syndrome, Multiple Sclerosis, Grave's disease, Giant cell artereitis, Ankylosing spondylitis, and Guillian Barre Syndrome; and (2) monitoring the disease in the subject.

To provide methods for treating psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA), e.g., non-radiographic axial spondyloarthritis (nr-axSpA) or ankylosing spondylitis (AS).SOLUTION: Methods are provided for treating PsA or axSpA using an IL-17 antagonist, such as an IL-17 antibody, such as secukinumab. Also provided herein are methods for inhibiting the progression of structural damage in PsA and axSpA patients using IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab.SELECTED DRAWING: None

The present disclosure provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, which inhibits TNFR1 and is contemplated to have utility as a therapeutic agent, e.g., for the treatment of inflammatory bowel disease, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiological central axis type spondylitis, and hidradenitis suppurativa. The invention also provides pharmaceutical compositions comprising the compounds disclosed herein, or pharmaceutically acceptable salts thereof. The present invention also relates to the use of said compounds or pharmaceutically acceptable salts thereof in the treatment and prevention of inflammatory bowel disease, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiological axial spinal arthritis and hidradenitis suppurativa, and a method for preparing a pharmaceutical product for this purpose.

The invention provides certain tetrahydropyran-imidazotriazine compounds of formula (I) as IL-17A inhibitors, pharmaceutical compositions thereof, and methods of using a compound of formula (I) to treat psoriasis, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, hidradenitis suppurativa, systemic lupus erythematosus, palmoplantar pustulosis (PPP), atopic dermatitis, asthma, non-infectious uveitis, or COPD.

This invention discloses a multi-drug composition for the treatment of ankylosing spondylitis. For the first time, this invention addresses the etiology of streptococcus-related diseases by proposing a synergistic treatment strategy combining a classic tumor necrosis factor antagonist (such as etanercept) with a narrow-spectrum antibiotic (benzathine penicillin). This approach breaks through the traditional treatment strategy that targets only the inflammatory pathway, providing a novel entry point for AS treatment.

This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as psoriasis, psoriatic arthritis or axial (spinal) spondyloarthritis (ax-SpA), including ankylosing spondylitis and non-radiographic ax-SpA, utilizing anti-IL-23A antibodies.

The disclosure is directed to pharmaceutical products and stable liquid compositions of IL-17 antibodies and antigen-binding fragments thereof, e.g., AIN457 (secukinumab), and processes of making these pharmaceutical products and compositions. The disclosure is also directed to the use of these pharmaceutical products and liquid compositions (e.g., as part of a kit having instructions for use) for the treatment of various IL-17-mediated disorders (e.g., autoimmune disorders, such as psoriasis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis).

The invention provides certain imidazotriazine compounds of formula I as IL-17A inhibitors, pharmaceutical compositions thereof, and methods of using a compound of formula I or II to treat psoriasis, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, hidradenitis suppurativa, systemic lupus erythematosus, palmoplantar pustulosis (PPP), atopic dermatitis, asthma, non-infectious uveitis, or COPD.

The present invention relates to methods of treating inflammatory diseases, including methods of treating IL-23 related diseases, in particular inflammatory diseases such as psoriasis, psoriatic arthritis or central axis (spinal) spondyloarthritis (ax-SpA), including ankylosing spondylitis and radionegative ax-SpA, using an anti-IL-23A antibody.

The disclosure is directed to pharmaceutical products and stable liquid compositions of IL-17 antibodies and antigen-binding fragments thereof, e.g., AIN457 (secukinumab), and processes of making these pharmaceutical products and compositions. The disclosure is also directed to the use of these pharmaceutical products and liquid compositions (e.g., as part of a kit having instructions for use) for the treatment of various IL-17-mediated disorders (e.g., autoimmune disorders, such as psoriasis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis).

The present application relates to a kind of ankylosing spondylitis polygenic risk score processing method, its main features are, the method includes the following steps: (1) the whole genome data of patient is collected, and it is carried out corresponding data preprocessing;(2) according to the preset proportion, the patient data and healthy control data obtained are divided into training set and test set, determine the association effect value between each genetic variant and ankylosing spondylitis AS, and obtain the corresponding association site;(3) extract the single nucleotide polymorphism SNP associated with ankylosing spondylitis AS, and the polygenic risk score PRS of individual is calculated using the weighted summation method;(4) the ankylosing spondylitis AS risk assessment of corresponding patient is carried out according to the polygenic risk score PRS obtained by calculation.This ankylosing spondylitis polygenic risk score processing method of the present application provides an ankylosing spondylitis related genetic variation and onset risk assessment system suitable for east Asian population.

The present invention in general relates to the field of antibody profiling in spondyloarthritis. In particular, the inventors found that antibody levels against selected peptides are raised in spondylarthritis patients, and herein provide a diagnostic method and kit comprising such peptides for use in the diagnosis of spondyloarthritis.